Martin D Haug

Prof. Dr. Martin D Haug

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in The Lancet
Verified
Journal Article
Closed access
IFIlario Fulco
Ilario Fulco
SMSylvie Miot
Sylvie Miot
MHMartin D Haug
Martin D Haug
ABAndrea Barbero
Andrea Barbero
AWAnke Wixmerten
Anke Wixmerten
IMIvan Martin
Ivan Martin

1 September 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
LRLina Acevedo Rua
Lina Acevedo Rua
MMMarcus Mumme
Marcus Mumme
CMCristina Manferdini
Cristina Manferdini
SDSalim Darwiche
Salim Darwiche
AKAhmad Khalil
Ahmad Khalil
KPKaroliina Pelttari
Karoliina Pelttari
Nasal chondrocyte–based grafts modulate osteoarthritis-like conditions in animal models and improve life quality in patients with knee osteoarthritis.

5 March 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
MMMarcus Mumme
Marcus Mumme
AWAnke Wixmerten
Anke Wixmerten
AIAlan Ivković
Alan Ivković
GPGiuseppe M. Peretti
Giuseppe M. Peretti
TYTayfun Yilmaz
Tayfun Yilmaz
IMIvan Martin
Ivan Martin
Cartilage lesions do not heal spontaneously and predispose to osteoarthritis. Functional cartilage tissues, engineered using autologous chondrocytes, have a therapeutic advantage over conventional cellular therapies in preclinical studies. Here, we tested whether ex vivo maturation of engineered grafts for cartilage repair leads to improved patient benefit. Using autologous nasal chondrocytes (NCs), we tested whether implantation of in vitro–matured NC-tissue-engineered cartilage (N-TEC) versus undifferentiated NC-cell-activated matrices (N-CAM) in focal cartilage lesions would result in a superior clinical outcome. The prospective, randomized, parallel, open-label phase-2 trial ( ClinicalTrials.gov , NCT02673905) enrolled 108 patients in five hospitals from four countries. Patients ranging in age from 30 to 46 years with full-thickness knee cartilage defects (size, 2.7 to 6.0 square centimeters) were equally randomized and treated with N-TEC or N-CAM. The primary preregistered outcome was the overall Knee Injury Osteoarthritis Outcome Score (KOOS) at 24 months. N-TEC, which underwent a longer NC culture time, was phenotypically, structurally, and functionally more like hyaline cartilage than N-CAM. The overall KOOS increased with clinical relevance in both groups compared with preoperative values. KOOS was higher at 24 months for N-TEC [85; interquartile range (IQR), 74 to 91] than for N-CAM (79; IQR, 65 to 85). N-TEC, but not N-CAM, was similarly effective in patients with larger defects or revision surgery. Radiologically, N-TEC resulted in a superior composition of both repair tissue and surrounding cartilage, whereas structural scores were similar. This trial validates the clinical efficacy of NC-based grafts for articular cartilage repair and supports the clinical relevance of engineering mature tissues, even for patients with more challenging cartilage defects.

29 January 2014 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
RWReto Wettstein
Reto Wettstein
MSMiodrag Savic
Miodrag Savic
GPGerhard Pierer
Gerhard Pierer
OSOliver Scheufler
Oliver Scheufler
MHMartin D Haug
Martin D Haug
DKDaniel Felix Kalbermatten
Daniel Felix Kalbermatten
Introduction: Chronic wounds are a major health-care issue, but research is limited by the complexity and heterogeneity in terms of wound etiology as well as patient-related factors. A suitable animal model that replicates the situation in humans is not available. Therefore, the aim of the present work is to present a standardized human wound model and the data of a pilot study of topically applied progenitor cells in a sacral pressure sore. Methods: Three patients underwent cell harvest from the iliac crest at the time of the initial debridement. Forty-eight hours after bone marrow harvest and debridement, the CD34+ selected cell suspension was injected into the wound. With the aid of a laser scanner, three-dimensional analyses of wound morphometry were performed until the defect was reconstructed with a local flap 3 weeks after debridement. Results: Decreases in volume to 60% ± 6% of baseline on the sham side and to 52% ± 3% of baseline on the cell side were measured. Histologic work-up revealed no signs of metaplastic, dysplastic, or neoplastic proliferation/differentiation after progenitor cell treatment. CD34+ cells were detected in the biopsies of day 0. Conclusions: The pressure sore wound model allows investigation of the initial 3 weeks after cell-based therapy. Objective outcome analysis in terms of wound volume and histology can be performed without, or with, minimal additional morbidity, and the anatomy of the sacral area allows a control and study side in the same patient. Therefore, this model can serve as a standard for wound-healing studies. Trial registration: ClinicalTrials.gov NCT00535548.

7 April 2020 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
MAM. Adelaide Asnaghi
M. Adelaide Asnaghi
LPLAURA POWER
LAURA POWER
ABAndrea Barbero
Andrea Barbero
MHMartin D Haug
Martin D Haug
RKRuth Köppl
Ruth Köppl
IMIvan Martin
Ivan Martin
The definition of quality controls for cell therapy and engineered product manufacturing processes is critical for safe, effective, and standardized clinical implementation. Using the example context of cartilage grafts engineered from autologous nasal chondrocytes, currently used for articular cartilage repair in a phase II clinical trial, we outlined how gene expression patterns and generalized linear models can be introduced to define molecular signatures of identity, purity, and potency. We first verified that cells from the biopsied nasal cartilage can be contaminated by cells from a neighboring tissue, namely perichondrial cells, and discovered that they cannot deposit cartilaginous matrix. Differential analysis of gene expression enabled the definition of identity markers for the two cell populations, which were predictive of purity in mixed cultures. Specific patterns of expression of the same genes were significantly correlated with cell potency, defined as the capacity to generate tissues with histological and biochemical features of hyaline cartilage. The outlined approach can now be considered for implementation in a good manufacturing practice setting, and offers a paradigm for other regenerative cellular therapies.

22 April 2023 in Cancer Treatment Reviews
Verified
Journal Article
Open access
WWWalter P. Weber
Walter P. Weber
Oreste D. GentiliniOreste D. Gentilini
Oreste D. Gentilini
MMMonica Morrow
Monica Morrow
GMGiacomo Montagna
Giacomo Montagna
JBJana de Boniface
Jana de Boniface
Michael GnantMichael Gnant
Michael Gnant
The aims of this Oncoplastic Breast Consortium and European Breast Cancer Research Association of Surgical Trialists initiative were to identify uncertainties and controversies in axillary management of early breast cancer and to recommend appropriate strategies to address them. By use of Delphi methods, 15 questions were prioritized by more than 250 breast surgeons, patient advocates and radiation oncologists from 60 countries. Subsequently, a global virtual consensus panel considered available data, ongoing studies and resource utilization. It agreed that research should no longer be prioritized for standardization of axillary imaging, de-escalation of axillary surgery in node-positive cancer and risk evaluation of modern surgery and radiotherapy. Instead, expert consensus recommendations for clinical practice should be based on current evidence and updated once results from ongoing studies become available. Research on de-escalation of radiotherapy and identification of the most relevant endpoints in axillary management should encompass a meta-analysis to identify knowledge gaps, followed by a Delphi process to prioritize and a consensus conference to refine recommendations for specific trial designs. Finally, treatment of residual nodal disease after surgery was recommended to be assessed in a prospective register.